Elevated Serum Thrombopoietin and Interleukin-6 Concentrations in Thrombocytosis Associated with Inflammatory Bowel Disease
- 1 July 1999
- journal article
- research article
- Published by Mary Ann Liebert Inc in Journal of Interferon & Cytokine Research
- Vol. 19 (7) , 757-760
- https://doi.org/10.1089/107999099313604
Abstract
Reactive thrombocytosis is a typical feature in inflammatory bowel disease (IBD). The question arose as to whether the normal negative feedback regulation of the concentration of thrombopoietin (TPO) in blood was altered in IBD patients. We measured serum immunoreactive TPO in 30 patients with active IBD, 29 patients with inactive IBD, and 56 healthy controls. The results were related to platelet and leukocyte counts and to the serum concentration of interleukin 6 (IL-6). Patients with active IBD exhibited significantly increased TPO levels (medians 112 pg/ml vs. 90 pg/ml in controls, p < 0.05) in association with thrombocytosis (428 platelets/nl blood vs. 241 platelets/nl blood in controls), leukocytosis, and increased IL-6 levels (12.9 pg/ml vs. 2.5 pg/nl in controls). In patients with inactive IBD, only platelets (322/nl) and leukocytes were above normal. Although the observation of increased TPO and IL-6 levels provides an explanation for the occurrence of thrombocytosis in IBD, the pathogenetic mechanisms underlying the elevated TPO level still need to be identified.Keywords
This publication has 36 references indexed in Scilit:
- Blood Thrombopoietin Levels in Clonal Thrombocytosis and Reactive ThrombocytosisThe American Journal of Medicine, 1998
- Binding and regulation of thrombopoietin to human megakaryocytesBritish Journal of Haematology, 1998
- Thrombosis in inflammatory bowel disease: clinical setting, procoagulant profile and factor V LeidenQJM: An International Journal of Medicine, 1997
- THROMBOPOIETIN: UNDERSTANDING AND MANIPULATING PLATELET PRODUCTIONAnnual Review of Medicine, 1997
- Interleukin-6 and megakaryocytopoiesis: an updateAnnals of Hematology, 1996
- Thrombotic vascular risk factors in inflammatory bowel disease.Gut, 1996
- Megakaryocyte growth and development factor. Analyses of in vitro effects on human megakaryopoiesis and endogenous serum levels during chemotherapy-induced thrombocytopenia.Journal of Clinical Investigation, 1995
- Coated mesalazine (5-aminosalicylic acid) versus sulphasalazine in the treatment of active ulcerative colitis: a randomised trial.BMJ, 1989
- Vascular Complications of Inflammatory Bowel DiseaseMayo Clinic Proceedings, 1986
- Platelet count: a simple measure of activity in Crohn's disease.BMJ, 1983